SDShaina J. D’souza

Shaina J. D’souza

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Shaina J. D’souza has a total of 32 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    CD4+ T cell protection against murine Salmonella infection is female-specific and estrogen-dependent

    by Shaina J. D’SOuza, Rebecca M. Horowitz, Louay Bachnak, Victoria E. Immethun, Matthew S. Godwin, Charlotte M. Hankin, Vanessa M. Limbert, David L. Bauer, Alex J. Plaisance, Avery M. Burke, et al.

    CD4+ T cells are necessary to control intracellular bacterial infections, but the role of sex in these infections is poorly understood. Here we show that upon challenge with Salmonella, a model intracellular bacterium, more male mice succumb to infection than females, despite having more Salmonella specific CD4+ T cells at later infection stages. Upon infecting mice lacking CD4+ T cells, survival differences reverse, which suggests that female and male CD4+ T cells play opposing roles during infection. Transfer of purified CD4+ T cells from either sex into CD4 deficient mice restores survival in females but decreases survival in males. Decreasing the hormone 17β-estradiol in females induces a more severe male-like phenotype. Exogenous 17β-estradiol induces both inflammatory and suppressive cytokines in CD4+ T cells from infected female mice and restores the protective function of T cells during infection. These findings reveal a sex difference in CD4+ T cell behavior during intracellular bacterial infection.

  • Open Access

    Establishment of isotype-switched, antigen-specific B cells in multiple mucosal tissues using non-mucosal immunization

    by John T. Prior, Vanessa M. Limbert, Rebecca M. Horowitz, Shaina J. D’souza, Louay Bachnak, Matthew S. Godwin, David L. Bauer, Jaikin E. Harrell, Lisa A. Morici, Justin J. Taylor, et al.

    Although most pathogens infect the human body via mucosal surfaces, very few injectable vaccines can specifically target immune cells to these tissues where their effector functions would be most desirable. We have previously shown that certain adjuvants can program vaccine-specific helper T cells to migrate to the gut, even when the vaccine is delivered non-mucosally. It is not known whether this is true for antigen-specific B cell responses. Here we show that a single intradermal vaccination with the adjuvant double mutant heat-labile toxin (dmLT) induces a robust endogenous, vaccine-specific, isotype-switched B cell response. When the vaccine was intradermally boosted, we detected non-circulating vaccine-specific B cell responses in the lamina propria of the large intestines, Peyer’s patches, and lungs. When compared to the TLR9 ligand adjuvant CpG, only dmLT was able to drive the establishment of isotype-switched resident B cells in these mucosal tissues, even when the dmLT-adjuvanted vaccine was administered non-mucosally. Further, we found that the transcription factor Batf3 was important for the full germinal center reaction, isotype switching, and Peyer’s patch migration of these B cells. Collectively, these data indicate that specific adjuvants can promote mucosal homing and the establishment of activated, antigen-specific B cells in mucosal tissues, even when these adjuvants are delivered by a non-mucosal route. These findings could fundamentally change the way future vaccines are formulated and delivered.


  • Open Access

    The Adjuvant Combination of dmLT and Monophosphoryl Lipid A Activates the Canonical, Nonpyroptotic NLRP3 Inflammasome in Dendritic Cells and Significantly Interacts to Expand Antigen-Specific CD4 T Cells

    by David L. Bauer, Louay Bachnak, Vanessa M. Limbert, Rebecca M. Horowitz, Robin L. Baudier, Shaina J. D’souza, Victoria E Immethun, Jonathan R Kurtz, Samuel B. Grant, James B. McLachlan

    Adjuvants are often essential additions to vaccines that enhance the activation of innate immune cells, leading to more potent and protective T and B cell responses. Only a few vaccine adjuvants are currently used in approved vaccine formulations in the United States. Combinations of one or more adjuvants have the potential to increase the efficacy of existing and next-generation vaccines. In this study, we investigated how the nontoxic double mutant Escherichia coli heat-labile toxin R192G/L211A (dmLT), when combined with the TLR4 agonist monophosphoryl lipid A (MPL-A), impacted innate and adaptive immune responses to vaccination in mice. We found that the combination of dmLT and MPL-A induced an expansion of Ag-specific, multifaceted Th1/2/17 CD4 T cells higher than that explained by adding responses to either adjuvant alone. Furthermore, we observed more robust activation of primary mouse bone marrow–derived dendritic cells in the combination adjuvant–treated group via engagement of the canonical NOD-like receptor family pyrin domain containing 3 (NLRP3) inflammasome complex. This was marked by a multiplicative increase in the secretion of active IL-1β that was independent of classical gasdermin D–mediated pyroptosis. Moreover, the combination adjuvant increased the production of the secondary messengers cAMP and PGE2 in dendritic cells. These results demonstrate how certain adjuvant combinations could be used to potentiate better vaccine responses to combat a variety of pathogens.